全文获取类型
收费全文 | 40861篇 |
免费 | 3562篇 |
国内免费 | 1074篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 2274篇 |
妇产科学 | 210篇 |
基础医学 | 3125篇 |
口腔科学 | 170篇 |
临床医学 | 4359篇 |
内科学 | 6031篇 |
皮肤病学 | 363篇 |
神经病学 | 402篇 |
特种医学 | 1177篇 |
外国民族医学 | 8篇 |
外科学 | 12971篇 |
综合类 | 5546篇 |
现状与发展 | 5篇 |
预防医学 | 1406篇 |
眼科学 | 142篇 |
药学 | 3510篇 |
19篇 | |
中国医学 | 1489篇 |
肿瘤学 | 2227篇 |
出版年
2024年 | 64篇 |
2023年 | 711篇 |
2022年 | 1023篇 |
2021年 | 1503篇 |
2020年 | 1581篇 |
2019年 | 1558篇 |
2018年 | 1503篇 |
2017年 | 1418篇 |
2016年 | 1555篇 |
2015年 | 1593篇 |
2014年 | 2564篇 |
2013年 | 3377篇 |
2012年 | 2062篇 |
2011年 | 2214篇 |
2010年 | 1899篇 |
2009年 | 1846篇 |
2008年 | 1858篇 |
2007年 | 1927篇 |
2006年 | 1836篇 |
2005年 | 1699篇 |
2004年 | 1485篇 |
2003年 | 1229篇 |
2002年 | 1099篇 |
2001年 | 954篇 |
2000年 | 743篇 |
1999年 | 630篇 |
1998年 | 522篇 |
1997年 | 530篇 |
1996年 | 491篇 |
1995年 | 492篇 |
1994年 | 459篇 |
1993年 | 377篇 |
1992年 | 346篇 |
1991年 | 291篇 |
1990年 | 243篇 |
1989年 | 230篇 |
1988年 | 194篇 |
1987年 | 183篇 |
1986年 | 140篇 |
1985年 | 193篇 |
1984年 | 157篇 |
1983年 | 93篇 |
1982年 | 97篇 |
1981年 | 95篇 |
1980年 | 72篇 |
1979年 | 63篇 |
1978年 | 73篇 |
1977年 | 45篇 |
1976年 | 56篇 |
1975年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
目的:观察糖尿病肾病不同分期内热证与肾功能及炎症指标的相关性。方法:收集202例糖尿病肾病患者的临床资料,采用酶联免疫吸附法检测微炎症指标,包括超敏C反应蛋白(high-sensitivity C-reactive protein,HS-CRP)、白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α),进行统计分析。结果:与非内热证组比较,中期、晚期内热证组24小时尿蛋白定量明显升高;晚期内热证组的血清肌酐明显升高,肾小球滤过率(glomerular filtration rate,GFR)明显降低;炎症因子CRP、IL-6、TNF-α随疾病进展均呈上升趋势;晚期内热证组与非内热证组比较,IL-6、TNF-α升高;中期HS-CRP与内热积分呈正相关,晚期TNF-α与内热积分呈正相关。结论:内热病机贯穿于糖尿病肾病的始终,与糖尿病肾病肾功能以及疾病进展密切相关;同时,内热积分与炎症因子HS-CRP、TNF-α的表达存在一定的相关性,这种相关性在疾病中期、晚期表现更加明显。 相似文献
32.
Objective To analyze the early mortality and related risk factors of new hemodialysis patients in Zhejiang province, and provide basis for reducing the death risk of hemodialysis patients. Methods The early mortality and related factors of new hemodialysis patients from January 1, 2010 to June 30, 2018 were retrospectively analyzed using the database of Zhejiang province hemodialysis registration. The early mortality was defined as death within 90 days of dialysis. Cox regression model was used to analyze the related risk factors of the early mortality in hemodialysis patients. Results The mortality was the highest in the first month after dialysis (46.40/100 person year), and gradually stabilized after three months. The early mortality was 25.33/100 person year. The mortality within 120 days and 360 days were 21.40/100 person year and 11.37/100 person year, respectively. The elderly (≥65 years old, HR=1.981, 95%CI 1.319-2.977, P<0.001), primary tumor (HR=3.308, 95%CI 1.137-5.624, P=0.028), combined with tumors (not including the primary tumor, HR=2.327, 95%CI 1.200-4.513, P=0.012), temporary catheter (the initial dialysis pathway, HR=3.632, 95%CI 1.806-7.307, P<0.001), lower albumin (<30 g/L, HR=2.181, 95%CI 1.459-3.260, P<0.001), lower hemoglobin (every 0.01 g/L increase, HR=0.861, 95%CI 0.793-0.935, P=0.001), lower high density lipoprotein (<0.7 mmol/L, HR=1.796, 95%CI 1.068-3.019, P=0.027) and higher C reactive protein (≥40 mg/L, HR=1.889, 95%CI 1.185-3.012, P=0.008) were the risk factors of early death for hemodialysis patients. Conclusions The early mortality of hemodialysis patients is high after dialysis, and gradually stable after 3 months. The elderly, primary tumor, combined with tumors, the initial dialysis pathway, lower albumin, lower hemoglobin, lower high density lipoprotein and higher C reactive protein are the risk factors of early death for hemodialysis patients. 相似文献
33.
S. Nishida J. J. Gaynor N. Nakamura F. Butt H. G. Illanes J. Kadono G. W. Neff D. M. Levi J. I. Moon G. Selvaggi T. Kato P. Ruiz A. G. Tzakis J. R. Madariaga 《American journal of transplantation》2006,6(1):140-149
A retrospective study of 1058 liver transplant recipients was performed to determine: (i) the incidence, etiology, timing, clinical features and treatment of refractory ascites (RA), (ii) risk factors for RA development, (iii) predictors of RA disappearance, (iv) predictors of survival following RA and (v) the impact of RA on patient survival. Sixty-two patients (5.9%) developed RA and its disappearance occurred in 27/62 cases. Patients having hepatitis C virus (HCV) had a significantly higher hazard rate of developing RA (p < 0.00001). No other baseline characteristic was associated with RA. Cox stepwise regression analysis of the hazard rate of RA disappearance found two significant factors: HCV recurrence as the reason for developing RA implied a poorer outcome (p = 0.006), whereas an unknown reason implied a favorable outcome (p = 0.02). In addition, survival following RA was significantly poorer among patients having bacterial peritonitis or HCV recurrence. Finally, the mortality rate was significantly (nearly 8.6 times) higher in patients following RA development while it was ongoing (p < 0.00001); however, if the RA disappeared, then the additional risk of death also disappeared. This study illustrates the importance of developing an optimal treatment strategy to (i) effectively treat RA if it develops and (ii) prevent hepatitis C recurrence. 相似文献
34.
It is important to determine when to use and when to avoid calcineurin inhibitors (CNIs). CNIs are associated with kidney dysfunction in some, but not all, transplant recipients. CNI-sparing protocols have their own drug-specific limitations. Two major clinical series suggest the benefit of routine CNI-sparing approaches, but our review suggests weaknesses in both. Ongoing studies are needed to determine which subgroups of recipients will benefit from CNIs. 相似文献
35.
目的 观察不同钙离子浓度的透析液对血液透析患者透析后血清钙离子水平及血压变化的影响,为肾功能衰竭血液透析患者的高钙血症及高血压的防治提供依据。方法 选择不同钙离子浓度的透析液,将维持性血液透析患者分为高钙组(1.75mmol/L)和低钙组(1.25mmol/L),比较患者每次透析前后脉搏、血压,同时抽查患者透析前后血钙及血肌酐浓度的变化。结果透析后两组患者血肌酐浓度均显著下降,透析前后差异均具有统计学意义(P〈0.01);高钙组患者透析后血钙较透析前升高,差异具有统计学意义(P〈0.01),而低钙组患者血钙比透析前略降低,差异无统计学意义(P〉0.05)。高钙组患者透析后较透析前收缩压、舒张压及平均动脉压都升高,差异均具有统计学意义(P〈0.05),而低钙组患者透析后较透析前收缩压、舒张压及平均动脉压都降低,差异均具有统计学意义(P〈0.05)。透析后两组血钙比较差异具有统计学意义(P〈0.01);透析后低钙组较高钙组患者的收缩压、舒张压及平均动脉压都降低,三者差异均具有统计学意义(P〈0.01)。结论透析液钙离子浓度与血液透析患者血清钙离子水平及血压呈正相关,低钙透析液透析有助于维持性血液透析患者高血压的控制。 相似文献
36.
37.
BACKGROUND: Recent guidelines suggest supplementation with ergocalciferol (vitamin D(2)) in chronic kidney disease stages 3 and 4 patients with elevated parathyroid hormone (PTH) levels and 25-hydroxyvitamin D (25OHD) levels <75 nmol/l. These guidelines are also applied to renal transplant patients. However, the prevalence rates of 25OHD deficiency and its association with PTH levels in renal transplant populations have not been extensively examined. We aimed to document the prevalence rates of 25OHD deficiency [defined by serum levels <40 nmol/l (<16 ng/ml)] and insufficiency [<75 nmol/l (<30 ng/ml)] in a single renal transplant centre, and examine its relationship with PTH levels. METHODS: Serum 25OHD and PTH concentrations were measured in 419 transplant patients attending a single renal transplant clinic over a 4-month period. Demographic and biochemical data were also collected, including serum creatinine, calcium, phosphate and albumin. Simple and multiple linear regression analysis were performed. RESULTS: In 27.3% of the patients, 25OHD deficiency was present, and 75.5% had insufficiency. On univariate analysis, 25OHD, serum albumin and estimated glomerular filtration rate (eGFR) were significantly associated with PTH levels (P < 0.0001, P = 0.004 and P < 0.0001, respectively). Multiple linear regression demonstrated that only 25OHD, eGFR and serum phosphate were significantly predictive of PTH levels (R(2) = 0.19, P < 0.0001). In this model, a 75 nmol/l increase in 25OHD will only result in a maximal reduction in PTH of 2.0 pmol/l. CONCLUSIONS: We conclude that 25OHD deficiency and insufficiency are common in renal transplant patients and may exacerbate secondary hyperparathyroidism. However, 25OHD, eGFR and phosphate only account for 19% of the variability in PTH levels. In addition, even a large increase in serum 25OHD levels is likely to result in only a small reduction in PTH. Therefore, alternative approaches to managing hyperparathyroidism in renal transplant recipients rather than supplementation with ergocalciferol are warranted. 相似文献
38.
39.
J. F. Trotter J. Campsen T. Bak M. Wachs L. Forman G. Everson I. Kam 《American journal of transplantation》2006,6(8):1882-1889
The purpose of this study is to determine the role of liver biopsy and outcome of patients undergoing donor evaluation for adult-to-adult right hepatic lobe living donor liver transplantation (LDLT). Records of patients presenting for a comprehensive donor evaluation between 1997 and February 2005 were reviewed. Liver biopsy was performed only in patients with risk factors for abnormal histology. Two hundred and sixty patients underwent a comprehensive donor evaluation and 116 of 260 (45%) were suitable for donation, 14 of 260 (5.4%) did not complete evaluation and 130 of 260 (50%) were rejected. Four patients underwent unsuccessful hepatectomy surgery due to discovery of intraoperative abnormalities. Between 1997 and 2001, the acceptance rate of donor candidates (63%) was higher than 2002-2005 (36%), p < 0.0001. Sixty-six of the 150 eligible patients (44%) fulfilled criteria for liver biopsy and 28 of 66 (42%) had an abnormal finding. Less than half of the patients undergoing donor evaluation were suitable donors and the donor acceptance rate has declined over time. A large proportion of the patients undergoing liver biopsy have abnormal findings. Our evaluation process failed to identify 4 of 103 who had aborted donor surgeries. 相似文献
40.
补肾排毒合剂治疗慢性肾衰竭营养不良60例临床观察 总被引:1,自引:0,他引:1
目的:观察补肾排毒合剂治疗慢性肾衰竭营养不良的疗效.方法:90例慢性肾衰竭营养不良患者随机分为治疗组60例和对照组30例,并设健康对照组30例.治疗组和对照组在综合治疗的基础上,治疗组加用补肾排毒合剂,对照组加用爱西特和百令胶囊.比较两组肾功能、营养状态和血浆瘦素、神经肽Y的变化.结果:治疗组治疗后BUN、Scr明显降低,与治疗前及对照组相比均有统计学差异(P<0.05).治疗组营养状态好转,与治疗前及对照组相比均有统计学差异(P<0.05).两组慢性肾衰竭营养不良患者治疗前Leptin、NPY水平均高于健康组(P<0.05),治疗后治疗组Leptin、NPY较治疗前下降,有统计学意义(P<0.05),但与对照组相比无统计学差异(P>0.05).结论:补肾排毒合剂治疗慢性肾衰竭营养不良疗效明显,可降低BUN、Scr,改善营养不良状态. 相似文献